Skip to main content
. Author manuscript; available in PMC: 2024 Mar 5.
Published in final edited form as: J Med Chem. 2021 Jul 26;64(15):10934–10950. doi: 10.1021/acs.jmedchem.1c00291

TABLE 1.

In vitro proteasome inhibition profiles by macrocyclic peptide epoxyketones. a

graphic file with name nihms-1968703-t0010.jpg
IC50 (nM)
LMP2 Y LMP7 X
YU102 105.2 ± 6.2 206.7 ± 5.5 >10,000 >10,000
KZR-504 157.9 ± 8.5 4,763 ± 54 >10,000 >10,000
DB-310 70.8 ± 1.7 589.9 ± 4.7 >10,000 >10,000
16 422.8 ± 68.0 ND >10,000 >10,000
17 129.3 ± 21.8 715.1 ± 88.0 1,516 ± 337 4,766 ± 549
18 414.5 ± 30.1 414.5 ± 62.7 341.8 ± 50.9 4,998 ± 704
19 167.7 ± 39.4 ND 2,686 ± 489 4,998 ± 704
20 184.1 ± 19.0 8,385 ± 847 399.3 ± 27.6 4,640 ± 781
21 412.8 ± 151.1 1,503 ± 398 >10,000 1,081 ± 223
22 563.4 ± 87.0 ND >10,000 4,640 ± 781
23 158.1 ± 30.4 ND >10,000 >10,000
24 522.6 ± 67.5 ND 5,773 ± 1007 >10,000
25 251.1 ± 35.8 ND >10,000 >10,000
26 69.4 ± 12.8 ND >10,000 >10,000
27 65.6 ± 14.5 ND >10,000 >10,000
32 2,131 ± 383 >10,000 >10,000 >10,000
33 237.7 ± 24.4 ND >10,000 >10,000
34 4,583 ± 601 ND >10,000 >10,000
35 261.5 ± 53.2 ND >10,000 >10,000
36 1,245 ± 200 ND >10,000 >10,000
a

The activity of individual proteasome subunits was measured using purified human 20S proteasomes and the respective fluorogenic substrates, Ac-PAL-AMC (for LMP2), Ac-nLPnLD-AMC (for Y), Ac-ANW-AMC (for LMP7), and Ac-WLA-AMC (for X). Data were obtained based on the results of 3 replicates per compound. N.D. denotes “not determined.”